ALSAF.PA Safe Orthopaedics SA

Healthcare Health Care Equipment & Supplies Euronext Paris
0.6400 EUR
Close of Oct 26, 2026
0.0022 2.60
Market cap
EUR 128K
P/E
-
P/B
0.40x
ROE
-
Dividend yield
-
Fundamental score
1.0/5

Ratios use the latest price and the fiscal year ending Dec 2025.

Is ALSAF.PA undervalued?

Graham number

The Graham number of Safe Orthopaedics SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Safe Orthopaedics SA fundamental analysis

3 of 11 checks passed

ROE 0/2

Negative ROE (-2325%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-57.14%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 2/2

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 0/2

The company has a high debt to equity ratio (2237%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

Revenue Growth 0/2

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

Net Profit Growth 0/2

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 1/2

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

Graham Number 1/1

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

Dividend Growth 0/2

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Dividend 0/2

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Buffet Intrinsic Value 0/1

The company's stock presents a potential concern as it appears overvalued (-16) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Safe Orthopaedics SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Safe Orthopaedics SA

Safe Orthopaedics SA, a medical technology company, develops and markets ready-to-use sterile implants and instrumentation for spinal surgery in France. It provides SteriSpine PS, for posture vixation; SteriSpine VA, a vertebral fracture solution; and SteriSpine CC/LC, an interbody fusion solution, including Walnut, Cedar, and Elm interbody cages. The company was founded in 2010 and is headquartered in Fleurieux-sur-l'Arbresle, France.

Full company profile